Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Pathogenesis and Novel Therapeutics in Asthma Volume II
share announcement

Pathogenesis and Novel Therapeutics in Asthma Volume II

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 3478

Special Issue Editor

Dr. Stanislawa Bazan-Socha

E-Mail Website
Guest Editor
Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Małopolskie, Poland
Interests: allergy; asthma; airway remodeling; autoimmune diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Asthma is a prevalent chronic inflammatory disease of the airways with complex etiology, mechanistic pathways, and variable clinical presentation. Such heterogeneity renders the search for targeted therapies. Currently, the best-known disease phenotype with tailored biological treatment is eosinophilic asthma. However, even in some of these patients, anti-IL5 treatment is ineffective. Furthermore, about a quarter of patients, especially those with a severe phenotype, develop progressive and irreversible airway obstruction, leading to persistent symptoms despite optimized treatment. Therefore, new therapeutic approaches are still needed, particularly in severe asthma. The Special Issue focuses on asthma research referring to modern personalized therapeutic opportunities. Particular interest is directed to novel asthma biomarkers, including molecular and epigenetic ones, providing new light on pathogenesis, phenotyping, and customized therapy in various airway inflammatory patterns of that disease. In addition, research articles on airway epithelial cell dysfunction, airway remodeling, and the overlap between asthma and chronic obstructive pulmonary disease are welcomed.

Dr. Stanislawa Bazan-Socha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma
  • pathogenesis
  • biomarkers
  • epithelial cells
  • airway remodeling
  • asthma/COPD overlap
  • biologics
  • new therapies

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

13 pages, 966 KiB  
Review
Obesity and Insulin Resistance in Asthma Pathogenesis and Clinical Outcomes
by Sabina Škrgat, Matevž Harlander and Miodrag Janić
Biomedicines 2024, 12(1), 173; https://doi.org/10.3390/biomedicines12010173 - 12 Jan 2024
Cited by 1 | Viewed by 932
Abstract
Common inflammatory ground links obesity, insulin resistance, and asthma. As recognition of their interplay, one worsening the natural course of the other, is recognised, questions remain about how to adequately address them altogether to improve clinical outcomes. The present manuscript sheds light on [...] Read more.
Common inflammatory ground links obesity, insulin resistance, and asthma. As recognition of their interplay, one worsening the natural course of the other, is recognised, questions remain about how to adequately address them altogether to improve clinical outcomes. The present manuscript sheds light on the problem, describing possible pathophysiological links, clinical views, and therapeutic challenges, raising questions about what remains to be done, and calling for multidisciplinary treatment of these patients to detect diseases early and adequately address them before they become full-blown and deteriorate their health and quality of life. Full article
(This article belongs to the Special Issue Pathogenesis and Novel Therapeutics in Asthma Volume II)
►▼ Show Figures

Figure 1

14 pages, 1064 KiB  
Review
T2-Low Asthma: A Discussed but Still Orphan Disease
by Francesca Peri, Alessandro Amaddeo, Laura Badina, Massimo Maschio, Egidio Barbi and Sergio Ghirardo
Biomedicines 2023, 11(4), 1226; https://doi.org/10.3390/biomedicines11041226 - 20 Apr 2023
Cited by 2 | Viewed by 1989
Abstract
Asthma affects 10% of the worldwide population; about 5% of cases are severe with the need for target therapies such as biologics. All the biologics approved for asthma hit the T2 pathway of inflammation. T2-high asthma is classified as allergic and non-allergic, whereas [...] Read more.
Asthma affects 10% of the worldwide population; about 5% of cases are severe with the need for target therapies such as biologics. All the biologics approved for asthma hit the T2 pathway of inflammation. T2-high asthma is classified as allergic and non-allergic, whereas T2-low asthma can be further defined as paucigranulocytic asthma, Type 1 and Type-17 inflammation and the neutrophilic form that accounts for 20–30% of all patients with asthma. Neutrophilic asthma’s prevalence is even higher in patients with severe or refractory asthma. We searched Medline and PubMed archives from the past ten years for articles with the subsequent titles: “neutrophilic asthma”, “non-type 2 asthma” and “paucigranulocytic asthma”. We identified 177 articles; 49 were considered relevant by the title and 33 by the reading of the abstract. Most of these articles are reviews (n = 19); only 6 are clinical trials. No study identified an effective treatment. We used the literature reported by these articles to search for further biologic treatments that target pathways different from T2. We identified 177 articles, 93 of which were considered relevant for the review and included in the present article. In conclusion, T2-low asthma remains poorly investigated in terms of biomarkers, especially as a therapeutic orphan disease. Full article
(This article belongs to the Special Issue Pathogenesis and Novel Therapeutics in Asthma Volume II)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop